With Novo Nordisk's obesity treatment Vegovy fully back in stock in December, sales are starting to rise, the Danish pharma reported Wednesday during its annual earnings call. Glucagon-like peptide 1 (GLP-1) Vigov's total scripts topped 37,000 weekly in mid-January, a hockey stick from year-end levels below 15,000 per week.
The new prescriptions come on top of the overall pace of sales of Novo obesity drug in 2022, though then-supply-constrained Vegovy was a part of that. Novo Nordisk's reported obesity segment sales accounted for DKK 10.7 billion ($1.58 billion) of Saxenda's total of DKK 16.9 billion ($2.49 billion), or about 63%.
